MetaCap

Scribe Therapeutics Inc. (SCTX)

NASDAQ: SCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

12.07-1.15 (-8.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

SCTX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$228.58M
EPS (TTM)
-$6.35
52-week range
12.00 – 39.60
Day range
12.00 – 13.40
Volume / Avg
301.40K / 403.27K
Beta
—
Next earnings
Dec 2, 2026

52-week range

$12.00$39.60

SCTX stock today

Scribe Therapeutics (SCTX) closed at $12.07 on Nov 20, down 8.70% (-$1.15), versus the S&P 500's 3.70% decline. At this level, SCTX sits near the bottom of its 52-week range of $12.00 to $39.60: 69.5% below the high, set on Aug 20, 2026 and 0.6% above the low. Scribe Therapeutics has posted a net loss over the last twelve months (EPS of -$6.35), so its P/E ratio is not meaningful.

The company is scheduled to report Sep/2026 results on Dec 2; analysts expect EPS of -$0.42.

Summary generated from market data by MetaCap's automated system. Methodology

About Scribe Therapeutics

Company profile

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Benjamin L. Oakes Ph.D.
Headquarters
Alameda, CA
Employees
77
IPO year
2026

Analyst forecast

Forecast

Consensus (4 analysts)

strong_buy

Avg. price target

$57.00+372.25%

  • Strong buy 0
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $50.00High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Next report
Dec 2, 2026
EPS estimate
$-0.42
Last reported (Sep/2026)
Dec 2, 2026
EPS actual vs est.
$-0.68 vs $-0.42
Surprise
-61.90%

SCTX news

All SCTX news

Scribe Therapeutics peers

Health Care sector
SCTX peer companies
CompanyPrice% ChgMarket capCompare
ALLOAllogene Therapeutics Inc.0.6277-5.88%$217.48Mvs SCTX
AUTLAutolus Therapeutics plc ADR0.9073-7.38%$241.65Mvs SCTX
PLXProtalix BioTherapeutics Inc. (DE)2.90-5.23%$244.52Mvs SCTX
LXEOLexeo Therapeutics Inc.2.96+0.34%$245.05Mvs SCTX
IPSCCentury Therapeutics Inc.1.17-11.74%$211.56Mvs SCTX
EDITEditas Medicine Inc.1.64-4.09%$253.12Mvs SCTX
SABSSAB Biotherapeutics Inc.2.81-3.44%$253.15Mvs SCTX
CABACabaletta Bio Inc.0.9361-7.32%$201.94Mvs SCTX

Indexes, lists and sector

Scribe Therapeutics stock FAQ

What is Scribe Therapeutics's stock price today?

SCTX last traded at $12.07 as of Nov 20, 4:00 PM EST, down 8.70% on the day. Prices are delayed at least 15 minutes.

When is Scribe Therapeutics's next earnings date?

Scribe Therapeutics is expected to report earnings on Wednesday, December 2, 2026. Analysts expect EPS of $-0.42.

Who is Scribe Therapeutics's CEO?

Dr. Benjamin L. Oakes Ph.D. is the chief executive officer of Scribe Therapeutics Inc., which has about 77 employees.

What is the SCTX 52-week high?

The 52-week high for SCTX is $39.60 and the 52-week low is $12.00. The stock is currently 69.5% below its high.

Compare SCTX